Abstract
Diabetes is closely relevant to muscle dysfunction. Chlorogenic acid (CGA) possesses various therapeutic functions in diabetic complications. However, no research implied the amelioration of CGA on diabetes-associated muscular atrophy. In this study, diabetic model was established by streptozotocin (STZ) to appraise roles of CGA (30 mg/kg/d for 8 weeks) on diabetes-associated muscular atrophy. Our researches demonstrated that CGA enhanced representative myocyte cross-sections, gastrocnemius weight and grip strength. In serum, CGA restricted CK, LDH, MDA, TNF-a and IL-6 levels, while elevated T-ACO, SOD and CAT levels against diabetic-evoked muscle damage. In skeletal muscle, CGA increased BCL-2 expression, while reduced FBXO-32, MURF-1, DDIT-3, GRP-87 and BAX expressions to improve diabetic muscular atrophy. In conclusion, CGA protected from diabetic-associated muscular atrophy through its bioactivities on the regulation of endoplasmic reticulum stress and apoptosis, and could be a powerful remedy approach in the ameliorations of diabetic muscle atrophy.
Publisher
Polish Pharmaceutical Society
Subject
Pharmaceutical Science,Pharmacology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献